Omnicell Inc (OMCL) fair value: what the stock is really worth
As of Oct 30, 2026: fair value (intrinsic value) of Omnicell Inc stock $3.16, price $36.65, that is 91.4% below the price, quality 59 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 1, 2026.
How to read this chart
60‑month range $24.63 – $183.62 · fair‑value band $2.16 – $4.16 · the $36.65 price screens above the $3.16 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 1, 2026.
Follow Omnicell in your weekly email
Every Wednesday you see whether Omnicell is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally.
Show moreShow less
It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process.
The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services.
In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform.
The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Stock analysis
Omnicell Inc (OMCL) currently trades at $36.65, while our model-based Fair Value estimate is $3.16, 91.4% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $15.97 per share, and 0 of the 24 models we run sit above the $36.65 price.
Bear case: the Earnings-Based group reads lowest at $0.4700, and 24 of the 24 models stay below the price. Data coverage for this calculation is low.
Scenario range: $2.16 (bear) to $4.16 (bull), the price of $36.65 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Omnicell Inc reported revenue of $1.2B in FY2025 versus $1.1B in FY2021, a compound +1.1%/yr. Reported net income was $2.1M in FY2025, compounding −59.7%/yr from FY2021.
Key figures
Market cap $1.7B Small · P/E ratio 38.2 · P/S ratio 1.36 · EPS (TTM) $0.9600 · Net margin 3.6% · Return on equity 3.5% · Return on assets (EBIT) 0.6% · Operating margin 4.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 30 out of 100 (low confidence).
What moves the price
The share trades about 29% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 4% fair-value upside, at −91%, OMCL screens richer than that median.
Fair Value models
Bear$2.16Fair Value $3.16Bull$4.16
Price $36.65 · Downside -91.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.8048 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+6.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.8%
Start year 2020 (pandemic). Over 10 years: +9.4% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
−22.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−22.8%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−50.1% vs −25.4%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 1%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+14.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +11.6% a year for the price and +0.6% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 121 stocks
Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score59 · Above median
Fair Value upside−91.4% · Bottom 25%
Profitability
Return on equity (12 months)3.5% · Above median
Return on assets0.1% · Below median
Net margin (12 months)3.6% · Above median
Operating margin (12 months)4.9% · Below median
Growth and dividend
Revenue growth (quarter YoY)−0.9% · Bottom 25%
Balance sheet
Debt / equity0.14× · Above median
Valuation Multiplesvs Health Information Services median · lower = cheaper
P/E (12 months)38.2× · Pricier than median
P/B1.37× · Cheaper than median
P/S (12 months)1.36× · Cheapest 25%
Price / free cash flow19.5× · Cheaper than median
EV/EBITDA16.2× · Pricier than median
PEG15.40× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 41
PAST (return on equity)14· sector 10
HEALTH (low debt)93· sector 98
DIVIDEND (yield)0· sector 36
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Omnicell Inc Fair Value". https://www.fairvalue-calculator.com/stock/OMCL
Frequently asked questions
Is Omnicell Inc (OMCL) overvalued or undervalued?
As of Nov 1, 2026, our model estimates a fair value of $3.16 versus a price of $36.65, about 91% lower (overvalued).
What is the fair value of OMCL?
Our model-based fair value for Omnicell Inc is $3.16 (as of Nov 1, 2026), built from audited fundamentals. The current price: $36.65.
What is the quality score of OMCL?
Omnicell Inc has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Omnicell Inc (OMCL)?
Our model-based price target is the fair value of $3.16 (as of Nov 1, 2026) from 24 valuation models. Cautious scenario $2.16, optimistic scenario $4.16. It is a calculation from audited fundamentals, not an analyst target.
What is the Omnicell Inc stock forecast for 2026?
Our models put fair value at $3.16, about 91% lower versus a price of $36.65 (overvalued). Cautious scenario $2.16, optimistic scenario $4.16. The calculation is refreshed regularly with new filings.
What is the revenue of Omnicell Inc (OMCL)?
Omnicell Inc reported trailing-twelve-month revenue of about $1.2B (latest available figure, as of Nov 1, 2026).
What growth is priced into Omnicell Inc (OMCL)?
For today's price to be fair in a discounted-cash-flow model, Omnicell Inc would have to grow free cash flow by +14.2 % per year for five years (discount rate 11.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +5.8 % per year. As of Nov 1, 2026.
What discount rate (WACC) does the fair value of OMCL use?
Our models discount Omnicell Inc at 11.2 %: a base by market capitalisation (small), damped by beta 0.99, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Omnicell Inc that is +14.2 % per year a year over ten years, using the same discount rate (11.2 %) and the same formula as our fair value.
How much growth has Omnicell Inc (OMCL) delivered so far?
Over the past 5 years revenue at Omnicell Inc grew +5.8 % a year. The price currently implies +14.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Omnicell Inc (OMCL) growing?
The median revenue growth in the sector is +6.4 % a year. That is the yardstick for the growth priced into Omnicell Inc (+14.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Omnicell Inc (OMCL)?
The free-cash-flow yield on the price is 5.14 %: that much free cash flow Omnicell Inc produces per unit of market value. When it exceeds the discount rate of our models (11.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Omnicell Inc (OMCL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Omnicell Inc it is $3.16 per share (as of Nov 1, 2026), against a price of $36.65. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Omnicell Inc stock overvalued or undervalued in 2026?
As of Nov 1, 2026, OMCL trades above its calculated fair value: price $36.65, fair value $3.16, a gap of about −91% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OMCL?
No. The price is what the market pays today ($36.65); the fair value is what the company's own numbers justify ($3.16). For Omnicell Inc the two are $33.49 per share apart. That gap is exactly why we show both numbers side by side.
How much is Omnicell Inc worth?
The market values Omnicell Inc at about $1.7B (market capitalisation, as of Nov 1, 2026). Per share that is $36.65; our models calculate a fair value of $3.16 per share.
What do the bullish and bearish scenarios say about OMCL?
Our models span a range for Omnicell Inc: cautious scenario $2.16, base $3.16, optimistic $4.16 per share (as of Nov 1, 2026, price $36.65). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of OMCL?
Omnicell Inc trades at a price-to-earnings ratio of 38.2 (as of Nov 1, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $3.16 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 174.5 (reported for FY2025: 916.3). Other multiples: PEG 15.4, P/B 1.4, P/S 1.4, EV/EBITDA 16.2.
What is the PEG ratio of OMCL?
The PEG ratio of Omnicell Inc is 15.40 (P/E divided by earnings growth, as of Nov 1, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Omnicell Inc (OMCL)?
Balance-sheet figures for Omnicell Inc (as of Nov 1, 2026): return on equity 3.5%, debt of 0.14 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is OMCL from its 52-week high?
Omnicell Inc trades at $36.65, about 29% below its 52-week high of $51.39 and 14% above the low of $32.23 (as of Oct 30, 2026). Distance from the high says nothing about value: that is what the fair value of $3.16 is for.
Which stocks are comparable to Omnicell Inc?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Omnicell Inc stock attractive at the current price?
The data as of Nov 1, 2026: price $36.65, calculated fair value $3.16 (−91%), Quality Score 59/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of OMCL calculated?
We run Omnicell Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $3.16, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Omnicell Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Omnicell Inc (OMCL)?
The closing price on Oct 30, 2026 was $36.65. Our model-based fair value is $3.16, about 91% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Omnicell Inc right now?
The price sits above even our optimistic bull case ($4.16). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($2.16 to $4.16) leaves room in how you read the outcome.
Key figures of Omnicell Inc
How large is the market capitalisation of Omnicell Inc (OMCL)?
The market capitalisation of Omnicell Inc is $1.7B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Omnicell Inc (OMCL)?
The price-to-sales ratio of Omnicell Inc is 1.36 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Omnicell Inc (OMCL)?
Earnings per share at Omnicell Inc are $0.9600 (price ÷ EPS = P/E 38.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Omnicell Inc (OMCL)?
The net margin of Omnicell Inc is 3.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Omnicell Inc (OMCL)?
The return on equity (ROE) of Omnicell Inc is 3.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Omnicell Inc (OMCL)?
On an EBIT basis the return on assets of Omnicell Inc is 0.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Omnicell Inc (OMCL)?
The operating margin of Omnicell Inc is 4.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Omnicell Inc (OMCL)?
Revenue at Omnicell Inc is growing −0.9% versus a year earlier (3y avg −2.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Omnicell Inc (OMCL)?
Earnings per share at Omnicell Inc are growing +100% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Omnicell Inc (OMCL) carry?
The net debt of Omnicell Inc is $7.8M (fiscal year 2025, ≈ 0.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Omnicell Inc in the live analysis
One click puts Omnicell Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 1, 2026